Mild | Moderate | Severe | |
Age (p = 0.019) | n (%) | n (%) | n (%) |
< 30 | 10 (43.5) | 9 (39.1) | 4 (17.4) |
30–45 | 26 (37.7) | 26 (37.7) | 17 (24.6) |
45–60 | 41 (26.6) | 62 (40.3) | 51 (33.1) |
60–75 | 57 (30.6) | 80 (43.0) | 49 (26.3) |
> 75 | 26 (17.1) | 69 (45.4) | 57 (37.5) |
Gender (p < 0.001) | |||
Male | 77 (22.1) | 144 (41.3) | 128 (36.7) |
Female | 83 (35.3) | 102 (43.4) | 50 (21.3) |
Hypertension (p = 0.015) | |||
No | 91 (33.7) | 107 (39.6) | 72 (26.7) |
Yes | 67 (22.9) | 132 (45.1) | 94 (32.1) |
Dyslipidemia (p = 0.006) | |||
No | 127 (32.2) | 159 (40.4) | 108 (27.4) |
Yes | 30 (18.9) | 75 (47.2) | 54 (34.0) |
Diabetes (p = 0.003) | |||
No | 134 (31.8) | 175 (41.5) | 113 (26.8) |
Yes | 23 (17.6) | 59 (45.0) | 49 (37.4) |
Immunodeficiency | |||
No | 283 (60.6) | 379 (81.0) | 273 (58.4) |
Yes | 8 (68.4) | 21 (102.6) | 11 (28.9) |
RASBa intake | |||
No | 10 (17.9) | 32 (57.1) | 14 (25.0) |
Yes | 50 (23.9) | 91 (43.5) | 68 (34.0) |
Mild-Moderate | Severe | ||
RASBa intake | n (%) | n (%) | |
No | 42 (75) | 14 (25) | |
Yes | 142 (67.9) | 67 (32.1) | |
ACEb intake (p = 0.046) | |||
No | 111 (65.3) | 59 (34.7) | |
Yes | 71 (77.2) | 21 (22.8) | |
ARBc intake (p = 0.004) | |||
No | 95 (77.9) | 27 (22.1) | |
Yes | 76 (60.8) | 49 (39.2) |